Prepping for COVID-19's Next Wave: Is the Glass Half Full or Half Empty? Biopharmaceutical Report IV Issue22_November 2020 COVID-19 didn’t disappear with summer temperatures, it just shifted locations and demog...
Lessons From Bergamo: Halting the Complement Cascade May Stop COVID-19 in Its Tracks Biopharmaceutical Report III Issue22_November 2020 Treatments for COVID-19 may be focusing on at the wrong elements of the disease, accor...
Fate and Celyad's CAR Therapies Offer Potential to Amplify Efficacy With Multiple Doses Biopharmaceutical Report II Issue22_November 2020 Fate Therapeutics’ (NASDAQ:FATE) and Celyad’s (NASDAQ:CYAD) natural killer (NK) cell bi...
Aurinia's Voclosporin Has Nephrotoxicity Concerns That Could Minimize First-Line Potential Biopharmaceutical Report I Issue22_November 2020 Aurinia Pharmaceutical’s (NASDAQ:AUPH) voclosporin has potential long-term nephrotoxicit...
Melanoma Trials Using Antibiotic or Microbiome Therapy Pretreatment Better Than Direct Combination Biopharmaceutical Report IV Issue21_April 2020 Early-phase melanoma trials testing microbiome approaches that leverage a broad- spectrum ...
Evofem's Amphora Requires 12-month Data to Convince Experts of Contraceptive Efficacy Biopharmaceutical Report III Issue21_April 2020 Evofem’s (NASDAQ:EVFM) contraceptive gel Amphora leaves experts needing detailed 12-month...
Haste Plus Speed: The Need to Ensure COVID-19 Vaccines Don't Make Infections Worse By Sandi Wong, Assistant Editor Biopharmaceutical Report II Issue21_April 2020 "THERE IS A HUGH DIFFERENCE BETWEEN THE POSSIBILITY THAT A...
Hidden Consequences of COVID-19: Why Small Biotechs Can't Just Wait This One Out By C. Simone Fishburn, Editor In Chief Biopharmaceutical Report I Issue21_April 2020 It’s still anyone’s guess as to how long the COVID-1...
Bayer’s Finerenone Use Will Face Off With SGLT2 Inhibitors By Manasi Vaidya, Reporter, New York Biopharmaceutical Report II Issue20_December 2019 Sodium-glucose cotransporter-2 (SGLT2) inhibitors’...
Novavax’s NanoFlu Has Tepid Expert Market Forecasts in Influenza Versus Sanofi’s Fluzone By Bernarda Tundzhay, Reporter, London Biopharmaceutical Report I Issue20_December 2019 Novavax’s (NASDAQ:NVAX) NanoFlu influenza vaccine...
